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Background: COPD is largely under-diagnosed and once diagnosed usually at a late stage. Early diagnosis is thoroughly
recommended but most attempts failed as the disease is marginally known and screening marginally accepted. It is a
rare cause of concern in primary care and spirometry is not very common. Exhaled carbon monoxide (eCO) is a
5-seconds easy-to-use device dedicated to monitor cigarette smoke consumption. We aimed to assess whether
systematic eCO measurement in primary care is a useful tool to improve acceptance for early COPD diagnosis.
Methods: This was a two-center randomized controlled trial enrolling 410 patients between March and May, 2013.
Whatever was the reason of attendance to the clinic, all adults were proposed to measure eCO during randomly chosen
days and outcomes were compared between the two different groups of patients (performing and not performing
eCO). Primary outcome was the rates of acceptance for COPD screening.
Results: Rate of acceptance for COPD screening was 28% in the eCO group and 26% in the other (P = 0.575). These
rates increased to 48 and 51% in smokers (current and former). eCO significantly increased the rate of clinics during
which a debate on smoking was initiated (42 vs. 24%, P = 0.001). eCO at 2.5 ppm was the discriminative concentration
for identifying active smokers (ROC curve AUC: 0.935). Smoking was the only independent risk factor associated with
acceptance for early COPD screening (OR = 364.6 (82.5-901.5) and OR = 78.5 (18.7-330.0) in current and former smokers,
respectively) while eCO measurement was not.
Conclusions: Early COPD diagnosis is a minor cause of concern in primary care. Systematic eCO assessment failed to
improve acceptance for early COPD screening.
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Increasing concerns about Chronic obstructive pulmon-
ary disease (COPD) are raised since it will be the fourth
leading cause of deaths by 2030 [1]. Under diagnosis of
COPD is a global problem, delaying adequate treatment
and the possibility of preventing physical, emotional and
socioeconomic consequences of the disease [2]. Multiple
attempts aimed at diagnosing COPD earlier but to date
none really penetrated the primary care in western
countries. Early detection of COPD is crucial for pro-
moting smoking cessation – which is more or less the* Correspondence: nicolas.molinari@inserm.fr
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unless otherwise stated.unique way to interfere with the natural history of the
disease. The under diagnosis of COPD is mostly related
to spirometry pitfalls which included- but not restricted
to-physicians- and patients-related factors. The reasons
for general practitioners (GP) not performing spirometry
might be limited access to the equipment, lack of ad-
equate training and time constraints [2]. On the patients
‘side, under diagnosis may be a result of the gradual
adaptation to increasing shortness of breath due to de-
clining lung function and a reluctance to seek for med-
ical advice before severe symptoms occur [3]. Moreover
minor knowledge of the disease towards the general
population leads to a non-discussion about shortness of
breath: “Surrounding COPD is an historical nihilism,
with patients and even their doctors establishing blame
and blatantly denying a medical problem exists” wasl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of the study population





(n = 410) (n = 194) (n = 216)
Female (%) 216 (53.3) 103 (53.9) 113 (52.8) .875c
Age (years) 60.6 ± 16.2 61.8 ± 15.8 59.5 ± 16.5 .144t
Smoking status .095c
Current smokers (%) 96 (23.4) 37 (19.1) 59 (27.3)
Former smokers (%) 130 (31.7) 61 (31.4) 69 (31.9)
Never smokers (%) 184 (44.9) 96 (49.5) 88 (40.7)
Pack-years 22.4 ± 15.9 22.4 ± 16.6 22.3 ± 15.6 .918m
Exhaled CO (ppm) 3.88 ± 7.01 NA 3.88 ± 7.01 NA
(t) Student t-test, (m) Mann-Whitney rank sum test, (c) Pearson’s Chi-squared test.
Categorical data are defined in number and percentage. Continuous data are
expressed as mean and standard deviation. Comparisons were made between
patients who ended up with an exhaled CO measurement and patients
without measurement.
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bility of the phenotype toward exacerbations rates iden-
tified a subgroup of COPD patients with a very low
disease-related risk in terms of hospitalizations, ex-
acerbation, accelerated decline in lung function or
comorbidity [4,5]. This fact did not help for persuad-
ing GPs that early COPD diagnosis is a worth effort.
Questionnaires have been developed and more or less
successfully developed but the issue raised by most
GPs associations dealt with an unacceptable number
of questionnaires that might be applied routinely for
most chronic diseases [6,7].
Assessing exhaled carbon monoxide (eCO) concentra-
tion is routinely used in tobacco weaning programs for
up to fifteen years. It was shown as a valuable noninva-
sive biomarker of cigarette smoke daily consumptionTable 2 Outcomes according to patient groups and smoking















9 (10) 82 (64) 91 (42) 0 (0) 47 (48) 4
Initiated by GP 2 53 55 0 40 4
Initiated by patient 7 29 36 0 7 7
Awareness for COPD,
n(%)
6 (7) 89 (70) 95 (44) 0 (0) 71 (72) 7
Initiated by GP 4 78 82 0 67 6




0 (0) 61 (48) 61 (28) 0 (0) 50 (51) 5
Comparisons are done with Pearson’s Chi-squared test or Fisher exact test (f).which passed through most validation studies. As it
stands, eCO is a 5 or 10 seconds measurement that
responds to most issues related to any tool: easy to do,
no contraindication, no expertise requirement, absolute
harmlessness, low cost [8].
As cigarette smoking remains the main cause of
COPD in western countries, we hypothesized that asses-
sing eCO in primary care will help GPs to improve
awareness about COPD that will introduce acceptance
for a COPD screening. We assumed that eCO assess-
ment in waiting rooms will improve the debate on
smoking and COPD during medical consultations.
Accordingly, we aimed to test this hypothesis in pri-
mary care through a two-center randomized controlled
trial.
Methods
Study design and population
A prospective multicenter study was conducted in two
outpatient primary care offices. All adult patients attend-
ing the outpatient clinic were consecutively included.
The study was proposed to any patients who turned up
at the clinics during the study period. Exclusion criteria
were refusal to participate after information and age
under 18 years old. Once attending the GP’s office, the
investigator presented the study and gathered the non
opposition approval. In the waiting room, a junior doc-
tor (not the GP) fulfilled the Case Report Form (CRF)
gathering the following information: age, gender, smok-
ing status (current, former: 6 months of smoking abstin-
ence, never). eCO concentration was assessed in the
waiting room on randomly chosen days and other days
considered as a control. In this study, we randomized
the days and not the subjects. The randomization of
days was done once for the study period to obtainstatus
Total p-value















7 (24) 9 (5) 129 (57) 138 (34) 0.001f 0.015 <0.001
0 2 93 95 NA 0.923 0.246
7 36 43 NA 0.002 <0.001
1 (37) 6 (3) 160 (71) 166 (40) 0.011f 0.633 0.128
7 4 145 149 NA 0.248 0.471
2 15 17 NA 0.177 0.045
0 (26) 2 (1) 111 (49) 111 (27) NA 0.616 0.575
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tively included with or without eCO assessment depend-
ing on the randomization table.
Afterwards, during medical consultations, the junior
doctor observed if concerns about smoking were raised
and if any awareness about COPD were discussed and
who initiated it (the patient or the GP). In the end both
doctors were the ones who would consider if the patient
declared acceptance for a COPD screening. However, we
didn’t know if the patients finally had an appointment
with the pulmonologist. Note that the GPs did not mod-
ify their usual practice as medical consultations were
conducted in a conventional way.
From March 2013 to May 2013 (3 months), 410 con-
secutive patients were screened and enrolled.Figure 1 Outcomes according to patient’s groups and smoking status.Ethics and consent
The local ethics committee “Comité de Protection des
personnes Sud-Mediterranee III” approved the study
design (code UF: 9134, register: 2013-A00104-41). Be-
cause of the non invasive design of this study, a non
opposition statement was obtained for all included
patients.
Statistical analysis
The primary outcome was the comparison of rates of
patient’s acceptance of a COPD screening between the
two different groups of patients (performing and not
performing eCO). The number of subjects needed was
calculated by assuming that this rate will reach 15%
when exhaled CO levels were measured and remained
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Assuming a two-sided alpha risk of 0.05 and a beta risk of
0.05, we calculated that at least 219 patients per group
would be required to identify a difference of 10%.
Outcome variables were acceptance for COPD screen-
ing, awareness for COPD and debate on smoking. Pre-
dictors were gender, age, smoking status, pack-years and
patient’s group (performing or not performing eCO).
Data are expressed as mean ± SD for continuous vari-
ables (age, pack-years, exhaled CO), or as number and
percentage for categorical variables (gender, tobacco
status). Continuous variables were compared using
Student’s t-test for normally distributed variables or
Mann-Whitney rank-sum test for non-normally distrib-
uted variables. Pearson’s Chi-squared test or Fisher exact
test was used to compare categorical variables. We did
not use any penalization for multiple testing procedures.Table 3 Univariate and multivariate analyses for each of the t
Variable Univariate
Odds-ratio
Outcome 1: debate on smoking
Female (%) 0.59 (0.39 - 0.91)
Age (years) 0.96 (0.94 - 0.97)
Tobacco
Current smokers 90.4 (38.6 - 211.5
Former smokers 12.1 (5.69 - 25.9)
Never smokers 1
Pack-years 1.01 (0.97 - 1.05)
Exhaled CO performing 2.24 (1.47 - 3.43)
Outcome 2: awareness for COPD
Female (%) 0.46 (0.31 - 0.69)
Age (years) 0.96 (0.95 - 0.97)
Tobacco
Current smokers 255.1 (89.8 - 724.
Former smokers 39.2 (16.2 - 94.9)
Never smokers 1
Pack-years 1.08 (1.01 - 1.17)
Exhaled CO performing 1.34 (0.90 - 1.99)
Outcome 3: acceptance for COPD screening
Female (%) 0.59 (0.39 - 0.88)
Age (years) 0.96 (0.94 - 0.97)
Tobacco
Current smokers 394.3 (89.3 - 896.
Former smokers 80.4 (19.1 - 338.0
Never smokers 1
Pack-years 1.04 (0.99 - 1.09)
Exhaled CO performing 1.26 (0.84 - 1.90)Multivariate models were established. Significance was
established at P< 0.05. Kernel density estimate was used
with a Gaussian kernel to estimate the exhaled CO dis-
tribution. The thresholds of CO values to predict
smokers and non smokers were assessed using a
Receiver Operating Characteristic (ROC) curve analysis.
Statistical analysis was performed by an independent
statistician, with R software (version 2.15.2).
Results
Between March and May 2013, 410 patients were in-
cluded in two different offices. Measurement of exhaled
CO was conducted in 216 patients. Patients’ characteris-
tics are presented in Table 1. Fifty-three percent were
females and the mean age (± standard deviation) was
61 ± 16 years. Twenty-three and 32% were current
and former smokers respectively. Within smokers andree outcomes
Multivariate
p-value Odds-ratio p-value
0.015 0.85 (0.48 - 1.53) 0.596
<0.001 0.98 (0.96 - 1.00) 0.104
<0.001 <0.001
) <0.001 38.3 (11.0 - 133.1) <0.001
<0.001 11.8 (5.32 - 26.2) <0.001
1
0.553 1.02 (0.96 - 1.05) 0.844
0.001 2.56 (1.45 - 4.51) 0.001
0.001 0.76 (0.41 - 1.39) 0.369
<0.001 0.99 (0.97 - 1.02) 0.676
<0.001 <0.001
9) <0.001 48.01 (10.7 - 215.0) <0.001
<0.001 35.8 (14.4 - 88.7) <0.001
1
0.032 1.03 (0.96 - 1.17) 0.082
0.150 0.98 (0.55 - 1.76) 0.959
0.011 1.21 (0.65 - 2.12) 0.548
<0.001 0.97 (0.95 - 1.02) 0.127
<0.001 <0.001
4) <0.001 73.67 (12.9 - 423.1) <0.001
) <0.001 87.1 (20.2 - 374.9) <0.001
1
0.058 1.06 (0.91 - 1.16) 0.067
0.263 0.93 (0.52 - 1.67) 0.995
Molinari et al. BMC Pulmonary Medicine  (2015) 15:44 Page 5 of 7former smokers, mean ± standard deviation cigarette
smoking history was 22 ± 16 pack-years.
Cigarette smoking was discussed with up to 138 differ-
ent patients (33.7%). Table 2 presents the outcomes
according to patient groups and smoking status. From
these 138 consultations, 91 have been subjected to CO
measurements (P < 0.001). Forty-three out of 138 consul-
tations, the debate was initiated by the patient himself
while 95 were introduced by the physician. Taking into
account the 166 debates in which awareness about
COPD was discussed, 95 had been subjected to CO
measurements (P = 0.128). COPD debate was mostly
introduced by the physician (149 out of 166). In the
end, 111 patients agreed on entering a COPD screen-
ing process, 61 being subjected to CO measurements
(P = 0.576). Figure 1 displays differences in outcomes
according to patient’s groups and smoking status.
Univariate and multivariate logistic regressions for the
three outcomes are presented in Table 3. Smoking status
and eCO measurement were independent factors associ-
ated with the occurrence of a debate on smoking duringFigure 2 Density estimation of exhaled CO for all (A), non smoker (B) andthe medical consultation with odds ratios of 34.8 (95%
CI = 11.0 to 133, P < 0.001) in current smokers and 11.8
(95% CI = 5.3 to 26.2, P < 0.001) in former smokers,
and 2.56 (95% CI = 1.45 to 4.51, P = 0.001) for eCO
assessment.
The only independent factor associated with accept-
ance for COPD screening was the smoking status.
When assessed, mean ± standard deviation (median,
interquartile range) eCO concentration was 3.88 ± 7.01
(1.00, [0 – 3.05]) exhaled CO (ppm). It reached 12.04 ± 9.00
(9.00, [4.00 – 19.00]) in current smokers, 0.82 ± 1.32
(0, [0 – 1.50]) for never smokers and 0.62 ± 1.29 (0,
[0 – 1.00]) for former smokers. Figure 2 presents the distri-
bution of the eCO for the overall population (Figure 2A),
the non smokers (never and former, Figure 2B) and current
smokers (Figure 2C). ROC correlating eCO value and
current smoking status was performed (Figure 3), showing
an optimal cutoff of eCO of over 2.5 ppm (AUC: 0.935,
95% CI [0.890-0.979], sensitivity: 0.867, specificity: 0.936,
positive predictive value of 52/62 (83.9%), negative predict-
ive value of 146/154 (94.8%)).smoker (C) patients.
Figure 3 Receiver Operating Characteristic curve (ROC) exhaled CO value and current smoking status.
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In this study, we evaluated a screening model for early
detection of patients with COPD assuming that measur-
ing eCO can lead to a debate on smoking consequences.
This investigation was to address a significant correl-
ation between eCO assessment and a debate during con-
sultations. This outcome was not achieved even though
eCO increased expression of cigarette smoking concerns.
Considering that smoking remains a key contributor
factor to develop COPD, it was found that CO measure-
ment device is a significant tool inducing a large increase
in smoking discussions. The measurement of exhaled
CO levels is an immediate and easy method of assessing
a patient’s smoking status as it may potentially introduce
a climate of concern.
Our study reveals that CO measurement in medical
primary care consultations (for other causes than COPD
symptoms) failed to promote patients acceptance for en-
tering into a COPD screening process, even in current/
former smokers. Potentially, this observation is related
to poor COPD knowledge in the general population –
and a weak concern in GP’s mind, and thus no clear
debate was initiated on this subject or if so, the in-
formation exchanged during the debates on COPD
was shallow. Nonetheless, rates of acceptance were
surprisingly high (nearly half of the smokers) mean-
ing that both patients and GPs behaviours could havebeen modified by the study itself, even in the group
of patients not performing eCO measurement. The
main limitation of the present study therefore is re-
lated to the lack of an observation period before the
study.
As a wide spread of this disease is foreseen in the fu-
ture and thus an increasing demand of medical consulta-
tions is expected, these results reinforce the need to
commit additional efforts among lung specialists into
sharing information about COPD among general popu-
lation and doctors [2].
Spirometry in primary care will probably be the next
step to achieve the goal of early COPD screening. PIKO-
6 and other attempts related to airflow assessment
mostly failed due to absence of funding and lack of ex-
pertise even though worth results were gathered [9-16].
Shortcoming spirometric pitfalls will probably require
conjugated efforts between respiratory physicians and
GPs but health care networks are currently working on
these aspects. Pharmacists and other health care pro-
viders are to be involved too [17-19].
The opportunity offered by the future lung cancer
screening programs that will be held in western coun-
tries should not be missed. These programs will poten-
tially promote generalized and potentially repeated
CT-scans in selected populations – who share the
same risk factors than for COPD (age and smoking
Molinari et al. BMC Pulmonary Medicine  (2015) 15:44 Page 7 of 7history). Findings unrelated to lung cancer have been
shown to improve health status and potentially reduce
deaths also because of these unexpected findings [20-23].
Successes of these programs are based on a clear and wide
awareness for cancer in the general population, largely as-
sociated with smoking. Emphysematous changes of the
lung parenchyma and other findings related to smoking
(airway wall thickening, suggestive signs of bronchiolitis
or desquamative interstitial pneumonia for example) are
potential triggers for COPD screening as this can more
easily be heard and become a cause for concern for both
patients and doctors than spirometry alone [22].
Conclusions
We conclude that generalized eCO measurement in
general practice failed to improve acceptance for early
COPD screening. Larger studies using a comparative
historical period are required to definitely conclude
whether or not we should give up this very simple
opportunity.
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